- $102.63m
- $56.66m
- $28.70m
- 26
- 24
- 50
- 24
Annual cashflow statement for Vaxart, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.2 | -70.5 | -108 | -82.5 | -66.9 |
| Depreciation | |||||
| Non-Cash Items | 2.96 | 8.55 | 13.9 | 12.2 | 75.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.81 | -2.12 | -6.7 | -8.85 | -62.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -23.8 | -59.8 | -94.8 | -70.5 | -44.8 |
| Capital Expenditures | -1.22 | -5.16 | -9.6 | -1.87 | -0.554 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.003 | -43.9 | -10.8 | 45.8 | -20.8 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.22 | -49.1 | -20.4 | 44 | -21.3 |
| Financing Cash Flow Items | 0.652 | 0 | — | -0.366 | -0.214 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 138 | 126 | 17.5 | 15.2 | 56.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 113 | 16.9 | -97.7 | -11.3 | -9.53 |